Denali Therapeutics Files 8-K
Ticker: DNLI · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-events, financial-reporting
Related Tickers: DNLI
TL;DR
Denali Therapeutics filed an 8-K on June 3, 2025, covering material agreements and shareholder votes.
AI Summary
Denali Therapeutics Inc. filed an 8-K on June 3, 2025, reporting on a material definitive agreement, submission of matters to a vote of security holders, and financial statements. The filing details the company's principal executive offices located at 161 Oyster Point Blvd., South San Francisco, CA 94080.
Why It Matters
This filing provides updates on significant corporate events and financial reporting for Denali Therapeutics Inc., which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate events and financial statements, not indicating immediate operational or financial distress.
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- 161 Oyster Point Blvd. (address) — Principal executive offices
- South San Francisco, California (location) — Principal executive offices location
- 001-38311 (company_id) — Commission File Number
FAQ
What are the main items reported in this 8-K filing by Denali Therapeutics Inc.?
The 8-K filing reports on the entry into a material definitive agreement, submission of matters to a vote of security holders, and financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 3, 2025.
What is the principal executive office address for Denali Therapeutics Inc.?
The principal executive office address is 161 Oyster Point Blvd., South San Francisco, California 94080.
What is the Commission File Number for Denali Therapeutics Inc.?
The Commission File Number for Denali Therapeutics Inc. is 001-38311.
What is the SIC code for Denali Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Denali Therapeutics Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Denali Therapeutics Inc. (DNLI).